A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Launched by XENOPORT, INC. · Sep 15, 2009
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. confirmed diagnosis of GERD by a gastroenterologist
- • 2. minimum of 3 months of GERD symptoms prior to screening.
- • 3. currently taking an FDA approved dose of PPI therapy for symptomatic GERD for at least 4 weeks prior to screening
- • 4. experienced partial relief of GERD symptoms while receiving approved dose and regimen of PPI therapy
- • 5. experienced GERD symptoms, defined as heartburn (with or without regurgitation or other GERD symptoms) on ≥ 3 days during the week prior to screening
- Exclusion Criteria:
- • 1. evidence of erosive esophagitis or erosive gastritis on upper gastrointestinal endoscopy during screening
- • 2. has not experienced any GERD symptom improvement after an adequate course of PPI treatment (at least 2 weeks)
- • 3. unstable or severe medical condition
About Xenoport, Inc.
XenoPort, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of neurological and autoimmune disorders. Leveraging its proprietary drug delivery technology, XenoPort aims to enhance the bioavailability and effectiveness of existing medications while minimizing side effects. The company is committed to advancing its pipeline of novel compounds through rigorous clinical trials, with a strong emphasis on scientific excellence and patient-centric approaches. XenoPort collaborates with healthcare professionals and research institutions to bring transformative solutions to patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Metairie, Louisiana, United States
Columbus, Ohio, United States
Ann Arbor, Michigan, United States
Scottsdale, Arizona, United States
San Diego, California, United States
Stanford, California, United States
Atlanta, Georgia, United States
Waterbury, Connecticut, United States
Huntsville, Alabama, United States
Charlotte, North Carolina, United States
Colorado Springs, Colorado, United States
Great Neck, New York, United States
Littleton, Colorado, United States
Binghamton, New York, United States
Fayetteville, North Carolina, United States
Germantown, Tennessee, United States
Tucson, Arizona, United States
Shreveport, Louisiana, United States
Annapolis, Maryland, United States
Lakewood, Colorado, United States
Lexington, Kentucky, United States
Brockton, Massachusetts, United States
Ogden, Utah, United States
Salt Lake City, Utah, United States
Clive, Iowa, United States
Raleigh, North Carolina, United States
Anaheim, California, United States
Lake Success, New York, United States
Jupiter, Florida, United States
Baton Rouge, Louisiana, United States
Lancaster, California, United States
Fargo, North Dakota, United States
Lafayette, Colorado, United States
Mission Hills, California, United States
Pembroke Pines, Florida, United States
Toronto, Ontario, Canada
Greensboro, North Carolina, United States
Lake Jackson, Texas, United States
San Antonio, Texas, United States
Madisonville, Kentucky, United States
Christiansburg, Virginia, United States
Guelph, Ontario, Canada
Egg Harbor Township, New Jersey, United States
Pittsburgh, Pennsylvania, United States
Norman, Oklahoma, United States
Uniontown, Pennsylvania, United States
Bellaire, Texas, United States
Charlottesville, Virginia, United States
Chandler, Arizona, United States
Sacramento, California, United States
Westlake Village, California, United States
Milford, Connecticut, United States
Monroe, Louisiana, United States
Brooklyn, New York, United States
Mesa, Arizona, United States
Chattanooga, Tennessee, United States
Sherwood, Arkansas, United States
Hagerstown, Maryland, United States
Johnson City, New York, United States
Logan, Utah, United States
Waukesha, Wisconsin, United States
Patients applied
Trial Officials
Study Director
Study Director
XenoPort, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials